Hayato Kawachi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hayato Kawachi has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Tadaaki Yamada
Department of Pulmonary Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
57 shared publications - Koichi Takayama
Department of Pulmonary Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
54 shared publications - Keiko Tanimura
Department of Respiratory Medicine, Fukuchiyama City Hospital, 231 Atsunakacho, Fukuchiyama City, Kyoto, Japan
33 shared publications - Naoki Furuya
St. Marianna University School of Medicine, Kawasaki, Japan
32 shared publications - Satoshi Watanabe
Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
32 shared publications - Yasuhiro Goto
Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan
32 shared publications
Latest Publications
- Open Access
- 7 February 2026
- Published by Elsevier in Lung Cancer
- Vol. 214, 109309
Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting
- 7 February 2026
- Published by Elsevier in Lung Cancer
- Vol. 214, 109309
Open AccessEfficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting
- 19 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 210, 108843
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database
- 19 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 210, 108843
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Table 4 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Grade 3 or higher AEs in the population adjusted by PSM
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Grade 3 or higher AEs in the population adjusted by PSM
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Discontinuation due to adverse events and ECOG Performance status deterioration due to treatment in the population adjusted by propensity score matching
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Discontinuation due to adverse events and ECOG Performance status deterioration due to treatment in the population adjusted by propensity score matching
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Incidence of Interstitial Pneumonitis as an adverse event
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Incidence of Interstitial Pneumonitis as an adverse event
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Incidence of interstitial pneumonitis as an adverse event in the population adjusted by propensity score matching
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Incidence of interstitial pneumonitis as an adverse event in the population adjusted by propensity score matching
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Table 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Table 1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Univariate and multivariate analysis of OS in patients treated with ICI and chemotherapy
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Univariate and multivariate analysis of OS in patients treated with ICI and chemotherapy
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Overall survival and Progression-free survival of 851 patients according to treatments
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Overall survival and Progression-free survival of 851 patients according to treatments
- Open Access
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Details of the antimicrobial administration history
- 23 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Details of the antimicrobial administration history